VR Logo

Alimera Sciences Inc. (ALIM) download report


Healthcare | Drugs & Pharma

Alimera Sciences Inc. (ALIM) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally.

IPO Date: 22-Apr-2010

Non-Exec. Chairman & Consultant: Mr. Charles Daniel Myers

Pres, CEO & Director: Mr. Richard S. Eiswirth Jr.

Listing: NASDAQ: ALIM

Country: United States

Headquarters: Alpharetta, GA

Website: https://alimerasciences.com

Key Facts

Market cap: $36.77 Mln

Revenue (TTM): $59.71 Mln

Earnings (TTM): $-6.68 Mln

Cash: $9.95 Mln

Total Debt: $43.60 Mln

Insider's Holding: 22.51%

Liquidity: Low

52 Week range: $3.94 - 9.79

Shares outstanding: 7,002,960

10 Years Aggregate:

  • CFO: $-187.76 Mln
  • EBITDA: $-155.95 Mln
  • Net Profit: $-224.24 Mln

Stock Performance

Time Period Alimera Sciences (ALIM) S&P BSE Healthcare S&P Small-Cap 600
YTD12.67-17.06-16.64
1 month1.05-3.28-6.45
3 months-2.69-10.69-12.22
1 Year-39.16-13.41-15.87
3 Years-25.1819.057.51
5 Years-22.249.236.63
10 Years-18.6912.3910.46
As on 28-Jun-2022
Year Alimera Sciences (ALIM) S&P Small-Cap 600 S&P BSE Healthcare
202121.5625.2720.87
2020-44.339.5761.45
2019-29.6320.86-3.55
2018-45.83-9.70-5.89
201723.1511.730.49
2016-55.3724.74-12.88
2015-56.32-3.3615.06